Home/ Stocks/ BTAI

BioXcel Therapeutics, Inc. Common Stock

BTAI XNAS

$1.43 -0.03 (-2.04%) ▼ 15-min delayed

Open

$1.46

High

$1.47

Low

$1.40

Volume

467.6K

Market Cap

$35.79M

About BioXcel Therapeutics, Inc. Common Stock

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 37 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$98.0K	$-30,911,000	$-2.18
Q2 2025	$120.0K	$-19,187,000	$-2.45
Q1 2025	$168.0K	$-7,254,000	$-1.50
FY 2024	$2.27M	$-59,599,000	$-23.51

Related Market News

No specific coverage for BTAI yet. Check out our latest market news or earnings calendar.

Get BTAI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BioXcel Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.